US10786261B2 - Shape memory polymer vessel occlusion device - Google Patents
Shape memory polymer vessel occlusion device Download PDFInfo
- Publication number
- US10786261B2 US10786261B2 US15/754,330 US201615754330A US10786261B2 US 10786261 B2 US10786261 B2 US 10786261B2 US 201615754330 A US201615754330 A US 201615754330A US 10786261 B2 US10786261 B2 US 10786261B2
- Authority
- US
- United States
- Prior art keywords
- smp foam
- foam
- metal
- smp
- backbone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 229920000431 shape-memory polymer Polymers 0.000 title claims abstract description 213
- 239000006260 foam Substances 0.000 claims abstract description 334
- 229910052751 metal Inorganic materials 0.000 claims abstract description 156
- 239000002184 metal Substances 0.000 claims abstract description 156
- 230000007704 transition Effects 0.000 claims abstract description 29
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 28
- XVNVIIRMSUKNKJ-CJAFCWQJSA-N (8r,9s,10r,11r,13r,14r,17s)-17-acetyl-11,14-dihydroxy-10,13-dimethyl-2,6,7,8,9,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@]1(O)CC[C@H](C(=O)C)[C@@]1(C)C[C@H]2O XVNVIIRMSUKNKJ-CJAFCWQJSA-N 0.000 claims description 27
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 24
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 22
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 230000004044 response Effects 0.000 claims description 18
- 239000004814 polyurethane Substances 0.000 claims description 15
- 229920002635 polyurethane Polymers 0.000 claims description 15
- 229910052697 platinum Inorganic materials 0.000 claims description 11
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 229910052741 iridium Inorganic materials 0.000 claims description 7
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 230000036772 blood pressure Effects 0.000 claims description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- 125000005442 diisocyanate group Chemical group 0.000 claims description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- 239000010937 tungsten Substances 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims 2
- 230000003073 embolic effect Effects 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000007246 mechanism Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000007943 implant Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 14
- 229910001000 nickel titanium Inorganic materials 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 230000017531 blood circulation Effects 0.000 description 11
- 239000011148 porous material Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 229910001220 stainless steel Inorganic materials 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000035602 clotting Effects 0.000 description 8
- 239000010935 stainless steel Substances 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- ZETYUTMSJWMKNQ-UHFFFAOYSA-N n,n',n'-trimethylhexane-1,6-diamine Chemical compound CNCCCCCCN(C)C ZETYUTMSJWMKNQ-UHFFFAOYSA-N 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 206010053567 Coagulopathies Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 206010053648 Vascular occlusion Diseases 0.000 description 6
- 201000002816 chronic venous insufficiency Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 208000021331 vascular occlusion disease Diseases 0.000 description 6
- 201000002282 venous insufficiency Diseases 0.000 description 6
- 208000036829 Device dislocation Diseases 0.000 description 5
- 229920001247 Reticulated foam Polymers 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000009477 glass transition Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 210000003752 saphenous vein Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- VZXPHDGHQXLXJC-UHFFFAOYSA-N 1,6-diisocyanato-5,6-dimethylheptane Chemical compound O=C=NC(C)(C)C(C)CCCCN=C=O VZXPHDGHQXLXJC-UHFFFAOYSA-N 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 4
- 102000002262 Thromboplastin Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000010102 embolization Effects 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- -1 polypropylene Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000008081 blood perfusion Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001223 reverse osmosis Methods 0.000 description 3
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960004418 trolamine Drugs 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- 229910000851 Alloy steel Inorganic materials 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229910001260 Pt alloy Inorganic materials 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 2
- 206010068149 Vessel perforation Diseases 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000012282 endovascular technique Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000010106 peripheral embolization Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008458 response to injury Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 230000000930 thermomechanical effect Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- AWNXKZVIZARMME-UHFFFAOYSA-N 1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound N=1C(NCC(C)(O)C)=NC=C(C=2N=C(NC=3C=C(Cl)N=CC=3)N=CC=2)C=1CC1CC1 AWNXKZVIZARMME-UHFFFAOYSA-N 0.000 description 1
- PZASAAIJIFDWSB-CKPDSHCKSA-N 8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1 PZASAAIJIFDWSB-CKPDSHCKSA-N 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- 229910017535 Cu-Al-Ni Inorganic materials 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000032767 Device breakage Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229920000079 Memory foam Polymers 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 244000208734 Pisonia aculeata Species 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 206010047050 Vascular anomaly Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003486 chemical etching Methods 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000109 continuous material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000004093 laser heating Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 239000008210 memory foam Substances 0.000 description 1
- 239000013580 millipore water Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000009734 pelvic venous congestion Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000009428 plumbing Methods 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 238000007632 sclerotherapy Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 206010041645 splenic artery aneurysm Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 210000002073 venous valve Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/1219—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices expandable in contact with liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/1214—Coils or wires
- A61B17/1215—Coils or wires comprising additional materials, e.g. thrombogenic, having filaments, having fibers, being coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
- A61B17/12172—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00526—Methods of manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00867—Material properties shape memory effect
- A61B2017/00871—Material properties shape memory effect polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00898—Material properties expandable upon contact with fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
- A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
- A61B2017/12063—Details concerning the detachment of the occluding device from the introduction device electrolytically detachable
Definitions
- Chronic venous insufficiency is caused by weakened venous valves that can no longer prevent backflow in peripheral veins that carry blood to the heart resulting in a sudden rise in venous pressure. This hypertension can lead to the formation of varicose veins as well as venous ulcers. The greater saphenous vein is the most common region treated for chronic venous insufficiency.
- Previous methods of treatment of the manifestations of chronic venous insufficiency include manual compression, surgical ligation and stripping, sclerotherapy, and endovenous ablation of the greater saphenous vein.
- Endovenous ablation has many downfalls. With endovenous ablation the patient experiences pain, either from the anesthetic injections or from the laser treatment. Further, recanalization may occur as the physician must uniformly ablate the whole cross-section of the vein and control the laser's pull-back speed. Many other complications may result such as deep vein thrombosis, bruising, dysesthesia, skin burns, bruising, thrombophlebitis, and nerve damage.
- FIGS. 1(A) -(C) and (D)-(F) depict deployment of embodiments.
- FIGS. 2(A) -(F) depict deployment of embodiments.
- FIGS. 3(A) -(B) depict a shape memory polymer foam with an anchor in pre and post expansion conditions.
- FIGS. 4(A) -(B) depict a shape memory polymer foam with an anchor in pre and post expansion conditions.
- FIGS. 5(A) -(B) depict a shape memory polymer foam with dual anchors in pre and post expansion conditions.
- FIG. 6 depicts an embodiment including flower shaped anchors.
- FIG. 7 shows thermomechanical analysis of various foam formulations.
- FIGS. 8(A) -(B) depict a shape memory polymer foam on a coil in pre and post expansion conditions.
- FIG. 9 depicts a shape memory polymer foam on a coil.
- FIG. 10 depicts a shape memory polymer foam on a conical coil.
- FIG. 11 depicts an image of an embodiment before the anchor of the embodiment has fully deployed.
- FIGS. 12(A) -(E) depict deployment of an embodiment.
- An embodiment provides a minimally invasive approach to achieve complete occlusion of arteries and veins within the peripheral vasculature.
- the cost, complexity, recurrence, risk, and complications of peripheral embolizations make the embodiments discussed herein highly desirable.
- An embodiment uses polyurethane shape memory polymer (SMP) foam to selectively occlude regions of vasculature where persistent blood flow may cause complications.
- SMP shape memory polymer
- the morphology and chemistry of the foam allows it to be compressed and loaded into an introducer and advanced through a catheter to the target region.
- the foam Upon contact with circulating blood, the foam expands (e.g., within 2, 4, 6, 8, or 10 minutes after contacting blood) to its original geometry and completely fills the vessel lumen.
- the procedure utilizes minimally invasive techniques.
- An embodiment includes one or more anchors placed proximal, distal, or at both locations relative to the device.
- the anchor(s) holds the device in place within the blood vessel.
- the anchor(s) is made of nitinol and/or platinum alloys.
- an object e.g., catheter, expanding balloon catheter
- an object e.g., catheter, expanding balloon catheter
- An embodiment of the SMP vessel occlusion device may utilize a number of delivery mechanisms.
- One such mechanism is a core wire that is placed within the volume of the foam implant and the implant is crimped over the core wire to create friction between the implant and core wire. The friction allows retraction and advancement of the device until it is fully expanded in the lumen of the treatment vessel. Once the device is fully expanded the friction is reduced enough to allow the core wire to be retracted through the volume of the device.
- Another such delivery mechanism is one in which the device is simply advanced through the catheter with a guidewire or pusher mechanism until the device is completely ejected from the delivery catheter.
- Such an embodiment may only include the foam without a core wire.
- the embodiment may be coupled with an anchor(s) (e.g., nitinol mesh) implanted separately from the foam upstream and/or downstream of the foam.
- Another delivery mechanism is one in which the proximal end of the device is attached to a pusher mechanism via an exposed stainless steel wire.
- an electrical current is applied to the pusher mechanism which causes electrolysis of the exposed stainless steel wire-effectively releasing the implant from the pusher mechanism.
- Embodiments of vascular occlusion devices discussed herein have a wide variety of indications, including the management of pelvic venous congestion, varicocele, varicosities associated with portal vein hypertension, traumatic hemorrhage, splenic artery aneurysms, and chronic venous insufficiency (CVI).
- CVI chronic venous insufficiency
- blood flow through specific vascular pathways presents potentially life-threatening consequences and extreme amounts of pain.
- physicians rely on occlusive devices to divert blood flow from susceptible vessels and minimize adverse outcomes.
- embodiments are useful for solve any manner of vascular issue brought on by a vascular anomaly.
- the foam systems may be used to block flow in non-biological contexts.
- foams coupled to one or more anchors in some embodiments
- foams may be used in general plumbing contexts or to otherwise quickly block fluid flow (where fluid flow may entail liquid or gas state flow).
- An embodiment is directed to an embolic device, wherein the device is used to stably occlude the flow of blood within a vessel undergoing treatment.
- the clot formation and stable occlusion occurs within 0-30 minutes after deployment of the device. For example, based on HDI content occlusion may occur in less than 60 seconds from the time the foam is deployed from the catheter.
- the device is typically delivered and deployed in the treatment region in a time frame of 5 seconds to 30 minutes. More than one device may be required and/or chosen to achieve complete vessel occlusion.
- the device is composed of a polyurethane SMP.
- the polymer is selected from N,N,N′,N′-Tetrakis (2-hydroxypropyl) ethylenediamine (HPED); 2,2′,2′′-nitrilotriethanol (TEA); 1,6-diisocyanatohexan (HDI); and trimethylhexamethylene diisocyanate (2,2,4- and 2,4,4-mixture) (TMHDI).
- the occlusion of a blood vessel occurs as a result of flow stagnation of the blood caused by the morphology of the device.
- the occlusion also occurs as a result of the tissue injury response of the endothelium of the vessel to the implantation of the device and the exposure of tissue factor binding sites.
- the occlusion occurs as a result of recirculation zones within the blood flow caused by the morphology of the implant. In other embodiments, the occlusion occurs as a result of platelet aggregation and activation throughout the volume of the device.
- An embodiment is directed to a delivery mechanism which delivers the embolic device to an area needing treatment.
- the delivery vehicle is a catheter, expanding balloon catheter, or a guidewire.
- the device is crimped over the core wire to provide sufficient friction between the implant and core wire to allow retraction and advancement of the device until it is fully expanded in the lumen of the treatment vessel.
- the core wire is selected from stainless steel, nitinol, steel alloy, polypropylene, polytetrafluoroethylene, or nylon wire, or a combination of these materials comprising a braided wire or coil. In some embodiments, the core wire is between 0.0005 and 0.050 inches in diameter.
- An embodiment provides a minimally invasive approach to achieve complete occlusion of blood vessels and prevent recurrence through the use of nitinol anchors on the proximal and distal ends of a polyurethane SMP foam. While the SMP foam encourages rapid hemostasis and healing, the device anchors ensure the foam remains in the treated vessel, minimizing the risk of embolization downstream of the target vessel and device migration.
- Material modifications such as plasma surface treatments, adding radiopaque fillers, and heat treating can be employed to minimize the time to hemostasis, optimize the design and dimensions of the device, ensure each component possesses adequate mechanical strength to prevent device fracture and dislocation from the target region, and to evaluate the deliverability, efficacy, and visualization of the device, via ultrasonography or X-ray in an in vitro model of a human great saphenous vein (GSV).
- GSV great saphenous vein
- An embodiment uses polyurethane SMP foam that is actuated at 37° C. (although other embodiments actuate at 36, 38, 39° C. or more), which means no external heating source is required to expand the foams after implantation.
- another embodiment has a higher transition temperature that requires the device to be actively heated via, for example, heated saline injection, radiofrequency heating, and/or laser heating to initiate expansion.
- the SMP vessel occlusion device is delivered using minimally invasive endovascular techniques in order to selectively occlude regions of vasculature where undesired persistent blood flow may cause complications.
- a SMP foam is crimped over a core wire and attached to a pusher system that allows the device to be navigated through the lumen of the catheter in order to reach the target site. Upon contact with blood, the device expands and resumes its pre-crimped geometry. This allows for a window of time between zero to thirty minutes for the delivery of the device to the treatment region. The foam expands upon exiting the catheter in order to fill the entire cross-section of the vessel. Once the foam completely expands, the pusher system can be retracted due to less friction between the foam and the core wire.
- thrombosis occurs within the entire volume of foam within 0 to 90 minutes.
- the porous morphology of the implant initiates the clotting cascade by creating many recirculation zones and flow stagnation in the blood stream.
- the clotting cascade is further stimulated by the expansion of the foam implant which damages the endothelium and exposes tissue factor binding sites.
- the expansion of the foam implant also triggers the foreign body response.
- An embodiment uses a pure foam device whereby a SMP foam is synthesized, reticulated, cut to the desired geometry using biopsy punches, mechanically conditioned using a heated stent crimper, dried in a freeze-dryer, and then crimped to its deliverable geometry. This allows the foam device to be delivered to the target region via an introducer, catheter, and guidewire.
- Another embodiment is directed towards areas of high flow including, but not limited to, arterial flow.
- An internal elastic wire that optionally runs through the middle of the foam is laser welded or epoxied to the external surface of the distal anchor.
- the proximal anchor is attached in the same manner as the distal anchor.
- Another embodiment contains anchors proximal, distal, or in both locations relative to the SMP foam.
- the anchors contain a longitudinal member that is inserted centrally through a cylinder of SMP foam, which is then coated with a neat polymer solution consisting of a combination of N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine (HPED), 2,2′,2′′-nitrilotriethanol (TEA), 1,6-diisocyanatohexan (HDI), and trimethylhexamethylene diisocyanate (2,2,4- and 2,4,4-mixture) (TMHDI) that acts as an epoxy attaching the SMP foam to the coil backbone.
- the neat polymer solution may itself constitute a SMP (which may be foams or may not be foamed).
- one version contains 100% hexamethylene diisocyanate (HDI) and another contains a mixture of HDI and trimethylhexamethylene diisocyanate (2,2,4- and 2,4,4-mixture) (TMHDI) for the isocyanate monomer in the polyurethane reaction.
- HDI hexamethylene diisocyanate
- TMHDI trimethylhexamethylene diisocyanate
- the less hydrophobic 100% HDI foam was made specifically for vessel implantation to allow for immediate self-actuation of the VOD in vivo without the need for external heating.
- the foam actuates at body temperature after exposure to moisture in the blood which causes a drop in the material's transition temperature.
- both foams were reticulated and chemically post-processed in the same manner Aside from their different hydrophobicities, these two foams share very similar mechanical properties and shape memory characteristics.
- the material is constrained by the side walls of the container and unconstrained from above as it rises. Due to these conditions and their ultra-low densities, the foams may have an anisotropic morphology.
- foams were fabricated as follows (although other methods may be used).
- Isocyanate (NCO) prepolymers were synthesized with appropriate molar ratios of N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine (HPED, 99%; Sigma-Aldrich Inc., St. Louis, Mo.), triethanolamine (TEA, 98%; Sigma-Aldrich Inc.), and hexamethylene diisocyanate (HDI, TCI America Inc., Portland, Oreg.).
- the prepolymers were reacted for 2 days with a temperature ramp from room temperature to 50° C. at a rate of 20° C./hr, held isothermally at 50° C. for 16 hours, and passively allowed to cool back to room temperature.
- a hydroxyl (OH) mixture was blended with the remaining molar equivalents of HPED and TEA. This mixture also contained deionized (DI) water (>17 M ⁇ cm purity; Millipore water purifier system; Millipore Inc.), and catalysts (T-131 and BL-22, Air Products and Chemicals, Inc., Allentown, Pa.).
- DI deionized
- Millipore water purifier system Millipore Inc.
- catalysts T-131 and BL-22, Air Products and Chemicals, Inc., Allentown, Pa.
- the NCO prepolymer and the OH mixture were combined in a foaming cup along with surfactants (DC 198 and DC 5943, Air Products and Chemicals, Inc., Allentown, Pa.) and the physical blowing agent, Enovate 245fa (Honeywell International, Inc., Morristown, N.J.).
- This solution was mixed in a FlackTek Speedmixer (FlackTek, Inc., Landrum, S.C.) and poured into a bucket to form a foam.
- the foam was cured at 60° C. for 5 minutes before passively cooling to room temperature for further processing.
- foam formulations and pore sizes were fabricated to create foams with differing crosslink densities, glass transition temperatures (Tg), rate of moisture plasticization, and subsequent foam expansion rates.
- Foam formulations are denoted as H20-H60, where the numerical value appearing after “H” corresponds to the ratio of HPED to TEA equivalents in the polymer premix. Both foam formulation and pore size were used to control the expansion rate of the foams and the resultant working time to enable catheter delivery.
- foams were cut into blocks 2 cm thick, 7 cm long, and 6 cm wide. These blocks were then reticulated using the same method described previously (Rodriguez, J.; Miller, M.; Boyle, A.; Horn, J.; Yang, C.; Wilson, T.; Ortega, J.; Small, W.; Nash, L.; Skoog, H.; and Maitland, D., Reticulation of low density SMP foam with an in vivo demonstration of vascular occlusion, Journal of the Mechanical Behavior of Biomedical Materials 40 (2014): 102-114).
- the foams were penetrated by a floating pin array while subjected to low amplitude, high frequency perturbations, which allowed the creation of pinholes in the foam pore membranes. These pinholes create interconnected pores throughout the foam which allow blood flow and eventual connective tissue deposition to penetrate throughout the entire device.
- the foams were cut with disposable biopsy punches (Sklar Surgical Instruments, West Chester, Pa., USA) for three different device sizes-6, 8, and 12 mm. These device sizes were used to enable delivery through 4, 5, and 6Fr catheters, respectively, and the ability to treat vessels with diameters between approximately 2-11 mm.
- the foams were cleaned to remove any plasticizers and unreacted monomers from the foams. Each cleaning cycle lasted 15 minutes and was performed under sonication in a 40° C. water bath. The first two cleaning cycles consisted of submerging the foams in 99% isopropyl alcohol (VWR, Radnor, Pa.).
- the foams were rinsed with reverse osmosis (RO) water before being cleaned in four cycles of Contrad 70 liquid detergent (Decon Labs, King of Prussia, Pa.). Each foam was then rinsed with RO water until no Contrad 70 residue was evident. Finally, the foams were cleaned for two cycles in RO water. After cleaning, the damp foams were frozen in a ⁇ 20° C. freezer for 12 hours before freeze-drying in a FreeZone Freeze Dryer (Labconco, Kansas City, Mo.) for 24 hours.
- RO reverse osmosis
- a coil anchor is incorporated into some embodiments of the peripheral embolic device (PED) to enable implantation in both arteries and veins with minimal risk of device migration.
- PED peripheral embolic device
- the mandrels were immediately quenched in room temperature water to set the final shape of the coil.
- the coils were removed from the mandrel and a straight section of the coil was manually threaded through the center of the foam before crimping. While immediately above the platinum/iridium coil includes a channel to receive the nitinol wire in other embodiments the platinum/iridium coil and nitinol wire are merely coupled to each other.
- Uni-axial and tri-axial reticulated SMP foam samples were cut into 20-30 mm long cylindrical samples using a 10 mm diameter biopsy punch.
- the samples were pre-conditioned by radially compressing to 1 mm diameter using a SC250 stent crimper (Machine Solutions Inc., Flagstaff, Ariz.) at 97° C. and heated to expand to their original shape.
- SC250 stent crimper (Machine Solutions Inc., Flagstaff, Ariz.) at 97° C. and heated to expand to their original shape.
- the SMP foam cylinders were then chemically etched, rinsed, and cleaned.
- the samples were dried in vacuum and stored in an air-tight container with desiccant.
- the cylindrical samples were cut to 8 mm diameter using fine-tip scissors and 10 mm long using a razor blade.
- Samples were then radially compressed to the minimum diameter of approximately 1 mm using the stent crimper at 97° C., cooled under compression to maintain the compressed shape, and stored in an air-tight container with desiccant until implantation in vivo.
- FIGS. 1A to 1C The device was placed inside the catheter for 5 min to allow the foam to begin expanding and then pushed out of the catheter using the 0.035′′ guidewire. This procedure resulted in expansion of the foam immediately as it emerged out of the catheter as shown in a preliminary benchtop in vitro demonstration ( FIGS. 1D to 1F ). Contrast enhanced fluoroscopy was used to determine when the device had been deployed, by observing the location of the guidewire and if possible, a lack of contrast agent in the vessel. After delivery into the vessel, the device expanded to its primary shape and subsequently blocked the vessel. The vessel occlusion time was defined as the time after device delivery until injected contrast agent ceased to flow through or past the device; at that point clotting is likely to have occurred. Vessel occlusion time was determined via iodinated contrast injections visualized with angiography 45 s after deployment and then at 30 s intervals thereafter.
- the uni-axial reticulated foam had an average occlusion time of 90 ⁇ 11 s and the tri-axial reticulated foam had an average occlusion time of 128 ⁇ 77 s.
- the uni-axial reticulated foam induced faster occlusion that the tri-axial reticulated foam. This result is not unexpected since blood flow is likely impeded more by the less reticulated foam, potentially resulting in more rapid clotting due to increased flow stagnation and surface area. Due to the great difference in occlusion time exhibited by the tri-axial foam relative to the uni-axial foam, the effects of the extent of reticulation on occlusion time are still being investigated.
- FIG. 1 shows a schematic diagram of endovascular deployment of and embodiment of the SMP foam vascular occlusion device (VOD): (A) the device is pushed near the 5F catheter tip (distal end of the catheter) by the guidewire 101 , (B) the guidewire pushes the self-actuating device 103 out of the catheter 102 , and (C) the deployed device fills the vessel lumen 104 .
- FIGS. 1 (D-F) show in vitro demonstration of an embodiment of VOD deployment showing immediate expansion of the VOD foam 102 ′ in 37° C. (body temperature) water in a silicone tube (3.5 mm inner diameter) after deployment from catheter 103 ′.
- FIG. 2 shows a bulk foam device navigated through the catheter 202 (A), distal tip of the device exposed to circulating flow (B), distal tip of foam 203 completely expanded and apposed to vessel wall (C), unsheathing the device (D), the device completely deployed (E), and subsequent delivery of a second device 205 (F).
- FIG. 3 shows a device embodiment that consists of a shape memory polymer foam 303 plug with a leading edge coil anchor 306 (distal) and a proximal radiopaque marker 307 .
- FIG. 4 shows a crimped (A) and expanded (B) device embodiment which consists of a shape memory polymer foam plug 403 with a distal coil anchor 406 that extends through the core of the device.
- FIG. 5 shows a device embodiment that consists of a shape memory polymer foam 503 plug with a proximal 506 and distal 507 coil anchor.
- the anchors include radiopaque markers 508 and/or 509 .
- FIG. 6 shows a device embodiment that consists of a shape memory polymer foam plug 603 with proximal and distal flower-shaped anchors 606 , 607 cut from a monolithic tube of nitinol.
- FIG. 7 shows thermomechanical analysis of various foam formulations used in device fabrication, which demonstrate the tunability of the glass transition temperature of the device.
- differential scanning calorimetry was used to assess the ability to control the activation temperature of embodiments, which corresponds to the Tg of the materials of the embodiments. It is critical that the actuation temperature of these devices is greater than the temperature at which they are stored to prevent premature expansion of the foams.
- the Tg for all foam formulations ranged between 49 and 70° C.
- FIG. 7 shows representative thermograms for each foam composition used, where H20-H60 correspond to foam compositions with 20-60% molar equivalents of HPED. The thermograms demonstrate a single transition with no indication of a secondary transition, as well as a nearly linear relationship between increasing Tg as the ratio of HPED to TEA also increases.
- the average Tg ranged from H20 (49.85° C.) to H60 (69.44° C.).
- H40, H50, and H60 foams There is a general trend of decreasing expansion rate, within the first three minutes of submersion in 37° C. water, as the crosslink density of the foam increases (higher HPED content). The first three minutes of exposure to aqueous environments is critical in embodiments designed to be delivered within three minutes after first contacting blood or saline. Pore size also had a dramatic effect on expansion rate where expansion rate decreased as the pore size decreased due to increased foam density delaying water diffusion into the foam matrix. However, regardless of pore size and foam composition, all samples experienced 100% shape recovery in less than 20 minutes.
- FIG. 8 shows a crimped and expanded image of a foam-over-coil embodiment of the embolization device where a coil 806 is placed centrally through the core of a cylindrical piece of foam 803 .
- FIG. 9 shows an illustration of the foam-over-coil embodiment of the embolization device where a coil 906 is placed centrally through the core of a cylindrical piece of foam 903 and there is a distal section of exposed coil without foam.
- An embodiment includes radiopaque markers 908 and/or 907 .
- FIG. 10 shows an illustration of the foam-over-coil embodiment of the embolization device where a coil 1006 is placed centrally through the core of a cylindrical piece of foam 1003 and the diameter of coil gradual increases towards one end of the device similar to a spiral.
- An embodiment includes radiopaque markers 1008 and/or 1007 .
- embodiments allow precise control of the actuation temperature of SMP foams by altering the ratio of HPED to TEA.
- the increase in Tg as the amount of HPED increases is a result of the increased crosslink density associated with additional HPED and the steric hindrance provided by the molecular structure of HPED which limits chain mobility.
- the ability to control the Tg of SMP foam devices is highly useful for controlling the actuation rate of the device when exposed to circulating blood. This provides a simple means of altering the expansion kinetics of the foam to satisfy the unique specifications required by clinicians for different device indications.
- An average burst pressure of human saphenous veins is approximately 1,575 mm Hg. Based on this burst pressure and a PED 8 mm in diameter and 2 cm long device, the radial force of the foams must not exceed 107N to prevent vessel rupture in the venous system. This maximum radial force assumes a uniform distribution of radial force exerted along the length and circumference of the device. Based on this information, radial force tests demonstrated that the SMP foams exert a radial force on the vessel wall that is drastically smaller than would be required for vessel rupture. This is also considering that the foams are oversized by 50% to the inner diameter of the vessel, which is the common sizing practice when selecting an appropriately sized vascular plug.
- embodiments are at least as stable as Cook Nester® Coils. Although embodiments provided equal or superior resistance to undesired thromboembolism, device stiffness testing demonstrated that the embodiments are significantly less stiff than current embolic plugs used on the market, such as the AVP II.
- Embodiments of the SMP foams provide sufficient echogenicity to enable delivery using ultrasound guidance.
- the ability to deliver these devices using ultrasound guidance also allows for embodiments consisting entirely of SMP foam with no metallic components that can still be delivered and visualized using endovascular techniques.
- ultrasound imaging provides a means of delivering these devices without subjecting the patient to any radiation or potential side effects of the contrast injections required during fluoroscopy.
- Embodiments discussed herein show the mechanical properties of the shape memory polymer PED device are safe and unlikely to cause vessel perforation or rupture. At the same time, these studies demonstrated that the likelihood of device migration and undesired thromboembolism to be minimal. Embodiments accomplished this while also demonstrating a significant reduction in overall device stiffness compared to commercially available vascular plugs, which allows embodiments to be delivered to tortuous vessels that may not be accessible using conventional embolic devices. Embodiments cause complete vessel occlusion and encourage rapid thrombus formation, and demonstrate ease of visualization of the PED using ultrasound and/or fluoroscopy and the like.
- FIG. 12(A) includes an embodiment similar to FIG. 3(A) .
- a coil in its primary shape
- the SMP foam has not yet been ejected or deployed from the catheter.
- FIG. 3(B) the SMP foam has been deployed from the catheter upstream of the coil.
- the foam is deployed within a cage structure (“expanded delivery tube”).
- This tube may have splines or struts that, upon no longer being constrained by the catheter, open radially to project force against the vessel walls (possibly helping spread apart walls that have partially collapsed).
- the splines may be superelastic.
- the splines may include, for example, stainless steel or nitinol.
- the foam expands to its primary shape while still within (partially or completely) the struts of the cage structure.
- the physician may withdraw the cage back into the catheter and in so doing, have the cage arms or splines collapse around the misplaced foam and withdraw the foam into the catheter.
- the guidewire used to deploy the foam from the “expanded delivery tube” and ultimately deliver the device to the vessel
- the cage may be separate from one another.
- the guidewire and cage may be withdrawn simultaneously, or the cage may be withdrawn while the guidewire position is maintained prior to the guidewire withdrawing into the catheter.
- the guidewire may remain deployed (thereby keeping the foam deployed) while the cage is withdrawn causing the cage to collapse within the catheter. This has begun to occur in FIG. 12(C) and is continuing in FIG. 12(D) .
- the foam remains coupled to the coil anchor (via a metal backbone) and, if the foam moves downstream, the foam will move towards the coil anchor.
- the guidewire is clearly shown further deployed (closer to anchor) than the cage.
- the guidewire may merely push against a proximal portion of a metal backbone (i.e., the guide wire is not fixedly coupled to the backbone) that couples to the anchor or the guidewire.
- the guide wire may have an electrolytic release from the backbone and the like (e.g., guidewire couples to the backbone at a node that can be terminated via electrolytic process/reaction).
- the guidewire may couple via threads whereby the guidewire and backbone have complementary threads for coupling to each other.
- FIG. 12(E) shows the catheter, cage, and guidewire being withdrawn away from the deployed anchor and foam (labeled “Implanted device”).
- the cage frame may be a monolithic design fabricated from a single, continuous material.
- the struts may be formed from a single, continuous tube, where the struts are cut and positioned from the tube.
- the cage may have 2-30 struts.
- the struts may have a free end (shown distal or downstream) and a fixed end where they couple to a portion of the tube that has not been cut. In other words, their distal ends may be free from each other while their proximal ends all terminate at a band that is a portion of a tube from which the arms were formed.
- the struts may be constructed of elastic, biocompatible materials having a high strain recovery.
- a shape memory alloy having a strain recovery of 3% may be used (however other embodiments are not so limited and may include shape memory elements with strain recovery of 4%, 6%, 8%, 10% or more).
- Materials that may be used include, but are not limited to: shape memory alloys; titanium alloys, such as nitinol; copper-base alloys, such as Cu—Al—Ni; platinum alloys, such as Fe—Pt; chromium-cobalt alloys, such as Co—Cr—Mo; cadmium-base alloys, such as Ag—Cd; shape memory polymers, such as urethane; and stainless steel.
- the struts may be comprised of combinations of materials; for example, the proximal segment may be nitinol, the intermediate segment may be stainless steel, and the distal segment may be Co—Cr—Mo.
- an embodiment entails cutting a plurality of slots into an elastic tube.
- Cutting slots in a tube, wire, or rod may create the form of struts.
- the struts may be cut by a laser or other precision cutting device.
- the device cage frame may be shape set. Shape setting may involve creating a permanent shape for the device cage frame.
- shape setting may include molding the device frame to an expanded shape to which the device returns when radial restrictions are removed, such as through deployment from a tube.
- the device frame shaping may include forming a device frame and heat treating the device frame.
- Device formation may be performed by setting the tube in a mold structure and compressing the tube so that the struts expand into a preconfigured shape.
- Spacers corresponding to desired structure length may be placed in the corresponding section of tube; for example, a 10 mm spacer may be placed in a section of tube corresponding a proximal structure, where the desired proximal structure length is 10 mm.
- An external frame tailored to the desired structure diameter may be placed around the corresponding section of tube.
- the tube may be compressed axially until the lateral struts contact the external frame and/or the internal radial struts contact the spacer.
- the process may be applied subsequently or concurrently to other sections of the device frame.
- the device After formation of the preconfigured shape, the device may be heat treated to create a permanent shape to which the device frame will return to once external restrictions are removed.
- Example 1 includes an embolic device, wherein the device is used to stably occlude the flow of blood within a vessel undergoing treatment.
- Example 2 includes the embolic device of example 1, wherein the clot formation and stable occlusion occurs within 0-30 minutes after deployment of the device.
- Example 3 includes the embolic device of example 1, wherein the device is delivered and deployed in the treatment region in a time frame of 5 seconds to 30 minutes.
- Example 4 includes the embolic device of example 1, wherein the device is composed of a polyurethane SMP.
- Example 5 includes the embolic device of example 4, wherein the polymer is fabricated using a combination of hexamethylene diisocyanate (HDI), trimethylhexamethylene diisocyanate (2,2,4- and 2,4,4-mixture) (TMHDI) N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine (HPED), and 2,2′,2′′-nitrilotriethanol (TEA).
- HDI hexamethylene diisocyanate
- TMHDI trimethylhexamethylene diisocyanate
- HPED 2,2,4- and 2,4,4-mixture
- HPED trimethylhexamethylene diisocyanate
- TAA 2,2′,2′′-nitrilotriethanol
- Example 6 includes the embolic device of example 1, wherein the occlusion occurs as a result of flow stagnation of the blood caused by the morphology of the device.
- Example 7 includes the embolic device of example 1, wherein the occlusion occurs as a result of the tissue injury response of the endothelium of the vessel to device implantation and the exposure of tissue factor binding sites.
- Example 8 includes the embolic device of example 1, wherein the occlusion occurs as a result of recirculation zones within the blood flow caused by the morphology of the implant.
- Example 9 includes the embolic device of example 1, wherein the occlusion occurs as a result of platelet aggregation and activation throughout the volume of the device.
- Example 10 includes the embolic device of example 1, wherein the device is made from a shape memory foam.
- Example 11 includes the embolic device of example 1, further comprising an anchor that holds the device in place within the blood vessel.
- Example 12 includes the embolic device of example 11, wherein the anchor is placed proximal, distal, or at both locations relative to the device.
- Example 13 includes the embolic device of example 11, wherein the anchor comprises nitinol, platinum, stainless steel, polycarbonate, or a combination of these materials.
- Example 14 includes a delivery mechanism, wherein the delivery mechanism delivers the embolic device of example 1 to an area needing treatment, and remains at the location until the embolic device has expanded to create an occlusion.
- Example 15 includes the delivery mechanism of example 14, wherein the delivery mechanism is a catheter, expanding balloon catheter, or a guidewire.
- Example 16 includes the delivery mechanism of example 14, wherein the device is crimped over the core wire to provide sufficient friction between the implant and core wire to allow retraction and advancement of the device until it is fully expanded in the lumen of the treatment vessel.
- Example 17 includes the delivery mechanism of example 14, wherein the core wire is a stainless steel, nitinol, steel alloy, polypropylene, polytetrafluoroethylene, or nylon wire, or a combination of these materials comprising a braided wire or coil.
- the core wire is a stainless steel, nitinol, steel alloy, polypropylene, polytetrafluoroethylene, or nylon wire, or a combination of these materials comprising a braided wire or coil.
- Example 18 includes the delivery mechanism of example 14, wherein the core wire is between 0.0005 and 0.050 inches in diameter.
- Example 19 includes the device of example 5 wherein the foam includes radiopaque fillers, such as iodine, tungsten, platinum, barium sulphate, or any combination of these compounds.
- radiopaque fillers such as iodine, tungsten, platinum, barium sulphate, or any combination of these compounds.
- Example 20 includes the device of example 5 wherein the morphology and surface chemistry of the device causes fibrin deposition and platelet aggregation in less than 180 seconds.
- Example 21 includes the anchor of example 12 wherein the anchor geometry comprises a helix, spiral, or a helix with gradually increasing diameters over the length of the device.
- Example 22 includes the anchor of example 12 wherein the anchor comprises a cylindrical tube that is cut such that it contains a plurality of struts that may extend outward from the original cylinder geometry.
- Example 23 includes the device of example 4 wherein the device is modified such that interconnected pathways are created through the SMP.
- Example 1a includes a system comprising: an outer conduit having proximal and distal ends; a shape memory polymer (SMP) foam having proximal and distal ends and that transitions from a secondary shape to a primary shape when the SMP foam is heated above its glass transition temperature (Tg); a metal backbone including: (a)(i) a first portion that extends from the SMP foam proximal end to the SMP foam distal end and which is generally covered by the SMP foam, and (a)(ii) a distal portion that extends distally from the SMP foam distal end and which is not covered by the SMP foam; wherein: (b)(i) SMP foam and the metal backbone are both included within the outer conduit adjacent to the outer conduit distal end; (b)(ii) the metal backbone distal portion transitions from a secondary shape that is uncoiled to a primary shape that is coiled; and (b)(iii) the metal backbone distal portion is in the metal backbone distal
- the outer conduit may include an introducer sheath or lumen that fits within a catheter or some other lumen.
- the system is delivered to the end user in a contained package that includes the SMP foam already “loaded” within the introducer sheath and near a distal end of the sheath so the SMP foam can be deployed from the sheath with minimal distance to traverse.
- the “distal” end is the end of the device furthest from the physician when the physician is deploying the device.
- the primary shape of the SMP foam may be an expanded cylinder such as the cylinder shown in the post-expansion diagram of FIG. 3 .
- the primary shape of the metal backbone distal portion may be a coil as shown in FIG. 3 .
- the Tg may depress due to plasticization.
- the metal backbone includes a portion (e.g., portion 310 ) that extends from the SMP foam proximal end to the SMP foam distal end and which is generally covered by the SMP foam 303 .
- the metal backbone may also include a portion 311 that extends distally from the SMP foam distal end 312 and which is not covered by the SMP foam.
- the metal backbone distal portion transitions from a secondary shape that is uncoiled.
- FIG. 11 shows the secondary shape (see “Distal Pt/Ir Coil”) when the distal anchor is still within a catheter (or at least a portion of the anchor is still in the catheter) and has not yet been unconstrained such that it may return to its primary shape of a coil.
- Tg refers to the specific “glass transition temperature” whereas the “transition temperature” can refer to the Tg, the melt transition, or a crystallization temperature, among others.
- the SMP foam actuates at the Tg but may actuate at melt temperatures in other embodiments.
- Example 1a includes a system comprising: an outer conduit having proximal and distal ends; a shape memory polymer (SMP) foam having proximal and distal ends and that transitions from a secondary shape to a primary shape when the SMP foam is heated above its transition temperature; a metal backbone including: (a)(i) a first portion that extends from the SMP foam proximal end to the SMP foam distal end and which is generally covered by the SMP foam, and (a)(ii) a distal portion that extends distally from the SMP foam distal end and which is not covered by the SMP foam; wherein: (b)(i) SMP foam and the metal backbone are both included within the outer conduit adjacent to the outer conduit distal end; (b)(ii) the metal backbone distal portion transitions from a secondary shape that is uncoiled to a primary shape that is coiled; and (b)(iii) the metal backbone distal portion is in the metal backbone distal portion secondary
- the transition temperature equals the Tg for the SMP foam.
- Example 2a includes the system of example 1, wherein the SMP foam is a polyurethane SMP foam that includes N,N,N′,N′-tetrakis (2-hydroxypropyl) ethylenediamine (HPED), triethanolamine (TEA), and hexamethylene diisocyanate (HDI).
- HPED N,N,N′,N′-tetrakis (2-hydroxypropyl) ethylenediamine
- TEA triethanolamine
- HDI hexamethylene diisocyanate
- the ratio of HPED to TEA may be used to tailor the expansion rate.
- Expansion rates may be short (e.g., 1, 3, 5, 7, 9 min) or longer (e.g., 20, 25, 30 min or longer).
- Embodiments may include, for example, a range of 20 molar percent HPED to TEA all the way up to 80 molar percent HPED to TEA.
- embodiments may have ratios of moles of HPED to TEA of 0.2-0.8. However, other embodiments go outside those bounds.
- SMP foam includes N,N,N′,N′-tetrakis (2-hydroxypropyl) ethylenediamine (HPED), triethanolamine (TEA), and trimethylhexamethylenediamine (TMHDI) with HPED contributing a higher molar ratio of hydroxyl groups than TEA.
- HPED N,N,N′,N′-tetrakis (2-hydroxypropyl) ethylenediamine
- TEA triethanolamine
- TMHDI trimethylhexamethylenediamine
- SMP foam includes N,N,N′,N′-tetrakis (2-hydroxypropyl) ethylenediamine (HPED), Glycerol, pentanediol, and hexamethylene diisocyanate (HDI).
- HPED N,N,N′,N′-tetrakis (2-hydroxypropyl) ethylenediamine
- Glycerol Glycerol
- pentanediol hexamethylene diisocyanate
- Example 3a includes the system of example 2 wherein the metal backbone distal portion includes an outer metal portion, including a channel, and an inner metal portion included within the channel.
- Example 4a includes the system of example 3, wherein: the metal backbone first portion also includes the inner metal portion but does not include the outer metal portion; and the inner metal portion is monolithic and extends from the SMP foam proximal end, to and through the SMP foam distal end, and into the channel of the outer metal portion distal to the SMP foam.
- the inner metal portion may be a long monolithic (formed of one piece without seams or welds) wire that extends through the foam (area 310 ) and into the channel of the outer metal portion (area 311 ) while the outer metal portion may be restricted to area 311 .
- the outer metal portion may include platinum or iridium to provide radioopacity, which may be lacking for the inner metal portion (which may include, for example, nitinol) and foam.
- the portions not covered by foam may include the outer metal portion over the inner metal portion and the parts that are covered by foam may only include the inner metal portion.
- both the SMP and platinum coil anchor provide sufficient echogenicity to allow visualization.
- Significant acoustic shadowing indicative of an acoustically dense material was witnessed, providing further evidence that the embodiment is likely to cause rapid occlusion upon expansion in vivo. This shadowing is the same phenomenon used by physicians to identify dense, calcified lesions within arteries with intravascular ultrasound (IVUS).
- Example 5a includes the system of example 4, wherein at least a portion of the outer metal portion is more radiopaque than both the inner metal portion and the SMP foam.
- Example 6a includes the system of example 5, wherein the inner metal portion is superelastic.
- the inner metal portion may include nitinol.
- Superelasticity may also be referred to pseudoelasticity. As used herein, it is a property unique to shape memory alloys where they can reversibly deform to strains as high as 10%. This deformation characteristic does not require a change in temperature (like the shape memory effect), but the material needs to be above the transformation temperature to have superelasticity.
- Example 7a includes the system of example 6, wherein: the SMP foam includes a proximal portion that includes the proximal end of the SMP foam and a distal portion that includes the distal end of the SMP foam; and one of the proximal and distal portions of the SMP foam fixedly adheres to the metal backbone first portion and another of the proximal and distal portions of the SMP foam slideably couples to the metal backbone first portion.
- the SMP foam may be epoxied or otherwise adhered to backbone portion 310 at areas 313 and/or 314 and/or 315 .
- Adhering the foam at only one of the locations allows the foam to travel along the backbone while expanding radially.
- the foam slightly shrinks linearly when expanding radially.
- adhering the foam at some location helps ensure the foam stays coupled to the anchor if, for example, a user opts to deploy the system such that the foam is located downstream of the anchor.
- Example 8a includes the system of example 7, wherein the SMP foam and the metal backbone distal portion are oriented with respect to each other and with respect to the outer conduit so the metal backbone distal portion deploys from the distal end of the outer conduit before the SMP foam deploys from the distal end of the outer conduit.
- the system is deployed from catheter 318 in the distal direction 316 into or towards downstream blood pressure (i.e., blood is moving in direction 317 ).
- the anchor 306 is able to form the “leading edge” and points “downstream” whereas foam 303 is located upstream of the anchor.
- foam 303 is located upstream of the anchor. This is beneficial in that any downstream movement of foam 303 will actually push the foam towards the anchor and in so doing will cause the coil to produce greater radial force 319 , thereby driving the coil further into the vessel thereby stabilizing the system and preventing the system from moving downstream.
- This added force into the endothelial lining of the vessel may further illicit a healing response described herein.
- Example 9a includes the system of example 8 comprising a proximal metal portion that is: (c)(i) coupled to the inner metal portion, (c)(ii) located proximal to the SMP foam, (c)(iii) included within the outer conduit, and (c)(iv) is more radiopaque than both the inner metal portion and the SMP foam.
- one such proximal metal portion may include node 307 of FIG. 3 . Also see the “proximal marker band” of FIG. 11 . In such a case, the physician can determine the location of the foam based on the “ghost” space between the band and the anchor (see “foam” of FIG. 11 ).
- Example 10a includes the system of example 8, wherein at least one of the proximal metal portion and metal backbone includes an outer diameter that is at least 50% of an inner diameter of the outer conduit.
- the “Proximal marker band” of FIG. 11 may comprise a diameter 60, 70, 80, or 90% of the catheter or outer conduit within which it resides. Therefore a guide wire or pushing rod cannot easily slip between the marker band and the catheter wall. As a result, the guide wire or pushing rod easily couples to the device and can efficiently push the device out of the catheter.
- Example 11a includes the system of example 8, wherein: the metal backbone first portion is aligned along an axis; and the metal backbone distal portion, in its primary shape, provides a radial force that is generally orthogonal to the axis and is greater than another radial force exerted by the SMP foam.
- Such an axis is axis 320 of FIG. 3 and such a radial force of the anchor is force 319 and the radial force of the foam is force 321 .
- the radial stiffness of each different sized anchor was compared to the stiffness of two conventional vascular plugs.
- the 8 mm devices exerted an average maximum radial force of 4.0N
- the AMPLATZERTM Vascular Plugs exerted an average maximum radial force of 15.8N when oversized by 50% to the target vessel.
- Microscopic imaging of the 8 mm PED anchor coil revealed that approximately 30% of the coil surface area is in contact with the vessel endothelium, which corresponds to 0.43 cm2 of surface area.
- the PED anchor Given the estimated surface area of coils in contact with the vessel lumen, the PED anchor would exert a pressure of approximately 700 mmHg on the vessel endothelium-less than half the pressure required to cause rupture in an autologous vein graft.
- a 16 mm AVP II was deployed within a flexible PVC tube with an inner diameter of 10 mm, it was estimated that approximately 0.85 cm2 of device surface area was in contact with the inner diameter of the tubing, resulting in a radial pressure of approximately 1,400 mmHg
- the proven safety and efficacy of the AVP II device that led to its FDA approval, and the markedly reduced radial force and pressure exerted by the PED anchor, it is unlikely that the PED coil anchor would cause vessel rupture or perforation in vivo.
- Example 12a includes the system of example 8, wherein the outer conduit includes an introducer sheath.
- Example 13a includes the system of example 8, wherein: the metal backbone first portion is aligned along an axis; and the SMP foam and the metal backbone distal portion are oriented with respect to each other so when upstream blood pressure forces the SMP foam towards the metal backbone distal portion the metal backbone distal portion, in its primary shape, presses radially outwards in a direction generally orthogonal to the axis and in response to the upstream blood pressure forcing the SMP foam towards the metal backbone distal portion.
- Example 14a includes the system of example 8 with the TEA contributing a lower molar ratio of hydroxyl groups to the polyurethane SMP foam than the HPED.
- Example 15a includes the system of example 8 with the TEA contributing a higher molar ratio of hydroxyl groups to the polyurethane SMP foam than the HPED.
- Example 16a includes the system of example 15, wherein the polyurethane SMP foam includes a diisocyanate component consisting of the HDI and no other diisocyanate component.
- TMHDI TMHDI
- Example 17a includes the system of example 8, wherein the outer metal portion includes at least one of platinum, palladium, tungsten, and iridium.
- Example 18a includes the system of example 8 comprising an additional outer metal portion proximal to the SMP foam and not covered by the foam, wherein: the additional outer metal portion includes an additional channel; the inner metal portion extends to and through the SMP foam proximal end and into the additional channel; and the inner metal portion that extends to and through the SMP foam proximal end and into the additional channel also transitions from a secondary shape that is uncoiled to a primary shape that is coiled.
- the inner metal portion may be a single nitinol wire that extends throughout the length of the foam and into platinum coatings (e.g., outer metal portions) on both ends of the inner metal portion wire.
- platinum coatings e.g., outer metal portions
- no marker bands may be needed as the physician can determine the location of the foam based on the “ghost” space between the two anchors.
- Example 19a includes the system of example 8, wherein the metal backbone distal portion primary shape that is coiled includes a conically shaped coil with a base of the conically shaped coil between the SMP foam and a vertex of the conically shaped coil.
- base 1024 may be ejected from the catheter or outer conduit after vertex 1025 .
- the base may be located upstream of the vertex.
- a “conically shaped coil” as used herein includes a frustoconical shape (the basal part of a solid cone or pyramid formed by cutting off the top by a plane generally parallel to the base).
- the coil of FIG. 3 may be conical with the base closer to the foam than the vertex or where the vertex is closer to the foam than the base.
- the coils of FIG. 5 wherein either or both of the coils of FIG. 5 may be conical with the base closer to the foam than the vertex or where the vertex is closer to the foam than the base
- Example 20a includes a method comprising: providing a system comprising: an outer conduit having proximal and distal ends; a shape memory polymer (SMP) foam having proximal and distal ends and that transitions from a secondary shape to a primary shape when the SMP foam is heated above its glass transition temperature (Tg); a metal backbone including: (a)(i) a first portion that extends from the SMP foam proximal end to the SMP foam distal end and which is generally covered by the SMP foam, and (a)(ii) a distal portion that extends distally from the SMP foam distal end and which is not covered by the SMP foam; wherein: (b)(i) SMP foam and the metal backbone are both included within the outer conduit adjacent to the outer conduit distal end; (b)(ii) the metal backbone distal portion transitions from a secondary shape that is uncoiled to a primary shape that is coiled; and (b)(iii) the metal backbone distal portion is
- Example 20a includes a method comprising: providing a system comprising: an outer conduit having proximal and distal ends; a shape memory polymer (SMP) foam having proximal and distal ends and that transitions from a secondary shape to a primary shape when the SMP foam is heated above its transition temperature; a metal backbone including: (a)(i) a first portion that extends from the SMP foam proximal end to the SMP foam distal end and which is generally covered by the SMP foam, and (a)(ii) a distal portion that extends distally from the SMP foam distal end and which is not covered by the SMP foam; wherein: (b)(i) SMP foam and the metal backbone are both included within the outer conduit adjacent to the outer conduit distal end; (b)(ii) the metal backbone distal portion transitions from a secondary shape that is uncoiled to a primary shape that is coiled; and (b)(iii) the metal backbone distal portion is in the
- Example 21a includes the method of example 20, wherein: the metal backbone distal portion includes an outer metal portion, including a channel, and an inner metal portion included within the channel; at least a portion of the outer metal portion is more radiopaque than both the inner metal portion and the SMP foam; the method further comprising determining a position of the SMP foam within the vessel in response to at least a portion of the outer metal portion being more radiopaque than both the inner metal portion and the SMP foam.
- Example 22a includes the system of example 8 including a plurality of resilient arm members that are free from one another at distal ends of the arm members and are fixedly coupled to each other at proximal ends of the arm members; wherein: the metal backbone first portion is generally aligned along an axis; at least a portion of the SMP foam is located within the plurality of arms such that a plane orthogonal to the axis intersects the SMP foam and the plurality of arms; the plurality of arms compresses within the outer conduit and expands radially when the arms deploy from the outer conduit.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
- Materials For Medical Uses (AREA)
- Filling Or Discharging Of Gas Storage Vessels (AREA)
Abstract
Description
TABLE 1 | ||||
Number of | ||||
Chemical | samples | |||
Nitinol pin mass | etch | tested | ||
Uni-axial | 1 g axial | No | 5 |
1 g axial | Yes | 5 | |
2 g axial | No | 5 | |
2 g axial | Yes | 5 | |
Tri-axial | 1 g axial, 1 g trans-axial | No | 5 |
1 g axial, 1 g trans-axial | Yes | 5 | |
2 g axial, 1 g trans-axial | No | 5 | |
2 g axial, 1 g trans-axial | Yes | 5 | |
Non-reticulated control | Not applicable | No | 5 |
In Vivo Vascular Occlusion Assessment
Foam Composition | Average Tg (° C.) | Standard Deviation | ||
H20 | 49.84 | 0.15 | ||
H30 | 53.33 | 0.58 | ||
H40 | 58.83 | 0.28 | ||
H50 | 62.49 | 0.26 | ||
H60 | 69.44 | 0.39 | ||
Foam | Device Diameter | Vessel Diameter | Radial Force |
Composition | (mm) | (mm) | (N) |
H40 | 4 | 2.7 | 0.08 ± 0.03 |
6 | 4.0 | 0.16 ± 0.03 | |
8 | 5.3 | 0.24 ± 0.05 | |
10 | 6.7 | 0.30 ± 0.05 | |
H50 | 4 | 2.7 | 0.13 ± 0.07 |
6 | 4.0 | 0.17 ± 0.04 | |
8 | 5.3 | 0.21 ± 0.04 | |
10 | 6.7 | 0.25 ± 0.03 | |
H60 | 4 | 2.7 | 0.20 ± 0.04 |
6 | 4.0 | 0.29 ± 0.07 | |
8 | 5.3 | 0.38 ± 0.05 | |
10 | 6.7 | 0.36 ± 0.09 | |
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/754,330 US10786261B2 (en) | 2015-09-04 | 2016-09-02 | Shape memory polymer vessel occlusion device |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562214767P | 2015-09-04 | 2015-09-04 | |
PCT/US2016/050097 WO2017040918A1 (en) | 2015-09-04 | 2016-09-02 | Shape memory polymer vessel occlusion device |
US15/754,330 US10786261B2 (en) | 2015-09-04 | 2016-09-02 | Shape memory polymer vessel occlusion device |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/050097 A-371-Of-International WO2017040918A1 (en) | 2015-09-04 | 2016-09-02 | Shape memory polymer vessel occlusion device |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/032,270 Continuation US11369385B2 (en) | 2015-09-04 | 2020-09-25 | Shape memory polymer vessel occlusion device |
Publications (2)
Publication Number | Publication Date |
---|---|
US20190015108A1 US20190015108A1 (en) | 2019-01-17 |
US10786261B2 true US10786261B2 (en) | 2020-09-29 |
Family
ID=58188484
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/754,330 Active 2037-05-01 US10786261B2 (en) | 2015-09-04 | 2016-09-02 | Shape memory polymer vessel occlusion device |
US17/032,270 Active US11369385B2 (en) | 2015-09-04 | 2020-09-25 | Shape memory polymer vessel occlusion device |
US17/846,449 Active 2036-10-16 US11944317B2 (en) | 2015-09-04 | 2022-06-22 | Shape memory polymer vessel occlusion device |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/032,270 Active US11369385B2 (en) | 2015-09-04 | 2020-09-25 | Shape memory polymer vessel occlusion device |
US17/846,449 Active 2036-10-16 US11944317B2 (en) | 2015-09-04 | 2022-06-22 | Shape memory polymer vessel occlusion device |
Country Status (6)
Country | Link |
---|---|
US (3) | US10786261B2 (en) |
EP (2) | EP4316386A3 (en) |
JP (5) | JP6517432B2 (en) |
CN (2) | CN112890904A (en) |
PL (1) | PL3344161T3 (en) |
WO (1) | WO2017040918A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3344161T3 (en) * | 2015-09-04 | 2024-05-06 | The Texas A&M University System | Shape memory polymer vessel occlusion device |
CN110381889B (en) * | 2017-03-14 | 2021-12-31 | 形状记忆医疗公司 | Shape memory polymer foam to seal the space around a valve |
WO2019075023A1 (en) * | 2017-10-10 | 2019-04-18 | The Texas A&M University System | Sheathed embolization device |
EP3595581A4 (en) | 2017-12-21 | 2021-01-13 | The Texas A&M University System | Vascular prosthesis for leak prevention during endovascular aneurysm repair |
US11399840B2 (en) | 2019-08-13 | 2022-08-02 | Covidien Lp | Implantable embolization device |
JP2022553929A (en) * | 2019-10-17 | 2022-12-27 | ザ テキサス エーアンドエム ユニバーシティ システム | Drug-eluting shape memory foam |
AU2021329380A1 (en) | 2020-08-21 | 2023-03-16 | Shape Memory Medical, Inc. | Mechanical detachment system for transcatheter devices |
CN112535510B (en) * | 2020-12-25 | 2021-10-26 | 上海拓舜医疗科技有限公司 | Bronchus plugging device system with foam-shaped matrix memory alloy frame structure |
WO2022209622A1 (en) * | 2021-03-31 | 2022-10-06 | テルモ株式会社 | Embolic material |
WO2023196331A1 (en) * | 2022-04-04 | 2023-10-12 | Baylor College Of Medicine | Devices of resorbable drug-eluting shape memory foam |
WO2024006419A1 (en) * | 2022-06-29 | 2024-01-04 | Shape Memory Medical, Inc. | Aortic dissection and aortic false lumen embolization device |
Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980514A (en) * | 1996-07-26 | 1999-11-09 | Target Therapeutics, Inc. | Aneurysm closure device assembly |
US6123715A (en) | 1994-07-08 | 2000-09-26 | Amplatz; Curtis | Method of forming medical devices; intravascular occlusion devices |
US20010025155A1 (en) | 1990-07-24 | 2001-09-27 | Inbae Yoon | Apparatus for ablation of the endometrium of the uterus |
US20020068950A1 (en) | 1999-05-13 | 2002-06-06 | Corcoran Michael P. | Occlusion device with non-thrombogenic properties |
US20030236533A1 (en) | 2002-06-20 | 2003-12-25 | The Regents Of The University Of California | Shape memory polymer actuator and catheter |
US20050065547A1 (en) | 2003-09-18 | 2005-03-24 | Cardia, Inc. | ASD closure device with self centering arm network |
WO2005053547A2 (en) | 2003-11-28 | 2005-06-16 | Cook Incorporated | Vascular occlusion methods, systems and devices |
CN1671330A (en) | 2002-07-31 | 2005-09-21 | 微温森公司 | Three-part coaxial vaso-occlusive device |
US20050234509A1 (en) | 2004-03-30 | 2005-10-20 | Mmt Medical, Inc. | Center joints for PFO occluders |
US20060009785A1 (en) | 2003-11-13 | 2006-01-12 | The Regents Of The University Of California | Shape memory polymer medical device |
US20060116713A1 (en) | 2004-11-26 | 2006-06-01 | Ivan Sepetka | Aneurysm treatment devices and methods |
US20060122646A1 (en) | 2004-12-08 | 2006-06-08 | Cardia, Inc. | Daisy design for occlusion device |
US20060135947A1 (en) | 2000-10-27 | 2006-06-22 | Pulmonx | Occlusal stent and methods for its use |
US20070010851A1 (en) | 2003-07-14 | 2007-01-11 | Chanduszko Andrzej J | Tubular patent foramen ovale (PFO) closure device with catch system |
US20090056722A1 (en) * | 2007-08-28 | 2009-03-05 | Betsy Swann | Methods and devices for occluding an ovarian pathway |
CN101479006A (en) | 2006-05-24 | 2009-07-08 | 切斯纳特医学技术公司 | System and method for delivering and deploying an occluding device within a vessel |
EP2248486A2 (en) | 2005-12-22 | 2010-11-10 | Symetis Sa | Device for occluding a hole in a body wall |
US20100324585A1 (en) | 2009-06-17 | 2010-12-23 | Coherex Medical, Inc. | Medical device for modification of left atrial appendage and related systems and methods |
US20110144686A1 (en) | 2003-10-02 | 2011-06-16 | Lawrence Livermore National Security, Llc | Shape Memory Polymer Foams for Endovascular Therapies |
CN102186426A (en) | 2008-10-13 | 2011-09-14 | 斯瑞克公司 | Vaso-occlusive coil delivery system |
US20120172973A1 (en) | 2010-12-30 | 2012-07-05 | Cook Medical Technologies Llc | Self-expanding occlusion device |
US20130231684A1 (en) | 2009-06-22 | 2013-09-05 | W.L. Gore & Associates, Inc. | Sealing device and delivery system |
US20130253634A1 (en) | 2003-10-02 | 2013-09-26 | The Regents Of The University Of California | Stent With Expandable Foam |
US20130253086A1 (en) | 2004-08-16 | 2013-09-26 | Lawrence Livermore National Security, Llc | Shape memory polymers |
US20130317541A1 (en) | 2012-05-24 | 2013-11-28 | Lawrence Livermore National Security, Llc | Device and method for treatment of openings in vascular and septal walls |
US20140371789A1 (en) | 2012-02-29 | 2014-12-18 | Cardiapex Ltd. | Minimally invasive surgical techniques |
US20180132856A1 (en) | 2015-04-23 | 2018-05-17 | Mark A. Wierzbicki | Biocompatible biomedical occlusion device |
JP2018526128A (en) | 2015-09-04 | 2018-09-13 | ザ テキサス エーアンドエム ユニバーシティ システムThe Texas A&M University System | Shape memory polymer container closure device |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6723108B1 (en) * | 2000-09-18 | 2004-04-20 | Cordis Neurovascular, Inc | Foam matrix embolization device |
US20050228417A1 (en) * | 2004-03-26 | 2005-10-13 | Teitelbaum George P | Devices and methods for removing a matter from a body cavity of a patient |
US20060116709A1 (en) * | 2004-11-26 | 2006-06-01 | Ivan Sepetka | Aneurysm treatment devices and methods |
ATE424952T1 (en) | 2006-04-27 | 2009-03-15 | Lns Sa | DEVICE FOR SEQUENTIALLY FEEDING BARS INTO A MACHINE TOOL |
US9566419B2 (en) * | 2009-04-08 | 2017-02-14 | Bayer Healthcare Llc | Body lumen occlusion device and method |
-
2016
- 2016-09-02 PL PL16843059.3T patent/PL3344161T3/en unknown
- 2016-09-02 CN CN202110186636.XA patent/CN112890904A/en active Pending
- 2016-09-02 EP EP23215439.3A patent/EP4316386A3/en active Pending
- 2016-09-02 US US15/754,330 patent/US10786261B2/en active Active
- 2016-09-02 WO PCT/US2016/050097 patent/WO2017040918A1/en active Application Filing
- 2016-09-02 JP JP2018511680A patent/JP6517432B2/en active Active
- 2016-09-02 CN CN201680064779.0A patent/CN108430345B/en active Active
- 2016-09-02 EP EP16843059.3A patent/EP3344161B1/en active Active
-
2019
- 2019-04-17 JP JP2019078450A patent/JP6720381B2/en active Active
-
2020
- 2020-06-17 JP JP2020104156A patent/JP6900556B2/en active Active
- 2020-09-25 US US17/032,270 patent/US11369385B2/en active Active
-
2021
- 2021-06-16 JP JP2021099840A patent/JP7130817B2/en active Active
-
2022
- 2022-06-22 US US17/846,449 patent/US11944317B2/en active Active
- 2022-08-24 JP JP2022133111A patent/JP7318081B2/en active Active
Patent Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010025155A1 (en) | 1990-07-24 | 2001-09-27 | Inbae Yoon | Apparatus for ablation of the endometrium of the uterus |
US6123715A (en) | 1994-07-08 | 2000-09-26 | Amplatz; Curtis | Method of forming medical devices; intravascular occlusion devices |
US5980514A (en) * | 1996-07-26 | 1999-11-09 | Target Therapeutics, Inc. | Aneurysm closure device assembly |
US20020068950A1 (en) | 1999-05-13 | 2002-06-06 | Corcoran Michael P. | Occlusion device with non-thrombogenic properties |
US20060135947A1 (en) | 2000-10-27 | 2006-06-22 | Pulmonx | Occlusal stent and methods for its use |
US20030236533A1 (en) | 2002-06-20 | 2003-12-25 | The Regents Of The University Of California | Shape memory polymer actuator and catheter |
CN1671330A (en) | 2002-07-31 | 2005-09-21 | 微温森公司 | Three-part coaxial vaso-occlusive device |
US20070010851A1 (en) | 2003-07-14 | 2007-01-11 | Chanduszko Andrzej J | Tubular patent foramen ovale (PFO) closure device with catch system |
US20050065547A1 (en) | 2003-09-18 | 2005-03-24 | Cardia, Inc. | ASD closure device with self centering arm network |
US20110144686A1 (en) | 2003-10-02 | 2011-06-16 | Lawrence Livermore National Security, Llc | Shape Memory Polymer Foams for Endovascular Therapies |
US20130253634A1 (en) | 2003-10-02 | 2013-09-26 | The Regents Of The University Of California | Stent With Expandable Foam |
US20060009785A1 (en) | 2003-11-13 | 2006-01-12 | The Regents Of The University Of California | Shape memory polymer medical device |
WO2005053547A2 (en) | 2003-11-28 | 2005-06-16 | Cook Incorporated | Vascular occlusion methods, systems and devices |
US20050234509A1 (en) | 2004-03-30 | 2005-10-20 | Mmt Medical, Inc. | Center joints for PFO occluders |
US20130253086A1 (en) | 2004-08-16 | 2013-09-26 | Lawrence Livermore National Security, Llc | Shape memory polymers |
US20060116713A1 (en) | 2004-11-26 | 2006-06-01 | Ivan Sepetka | Aneurysm treatment devices and methods |
US20060122646A1 (en) | 2004-12-08 | 2006-06-08 | Cardia, Inc. | Daisy design for occlusion device |
EP2248486A2 (en) | 2005-12-22 | 2010-11-10 | Symetis Sa | Device for occluding a hole in a body wall |
CN101479006A (en) | 2006-05-24 | 2009-07-08 | 切斯纳特医学技术公司 | System and method for delivering and deploying an occluding device within a vessel |
US20090056722A1 (en) * | 2007-08-28 | 2009-03-05 | Betsy Swann | Methods and devices for occluding an ovarian pathway |
CN102186426A (en) | 2008-10-13 | 2011-09-14 | 斯瑞克公司 | Vaso-occlusive coil delivery system |
US20100324585A1 (en) | 2009-06-17 | 2010-12-23 | Coherex Medical, Inc. | Medical device for modification of left atrial appendage and related systems and methods |
US20130231684A1 (en) | 2009-06-22 | 2013-09-05 | W.L. Gore & Associates, Inc. | Sealing device and delivery system |
US20120172973A1 (en) | 2010-12-30 | 2012-07-05 | Cook Medical Technologies Llc | Self-expanding occlusion device |
US20140371789A1 (en) | 2012-02-29 | 2014-12-18 | Cardiapex Ltd. | Minimally invasive surgical techniques |
US20130317541A1 (en) | 2012-05-24 | 2013-11-28 | Lawrence Livermore National Security, Llc | Device and method for treatment of openings in vascular and septal walls |
US20180132856A1 (en) | 2015-04-23 | 2018-05-17 | Mark A. Wierzbicki | Biocompatible biomedical occlusion device |
JP2018526128A (en) | 2015-09-04 | 2018-09-13 | ザ テキサス エーアンドエム ユニバーシティ システムThe Texas A&M University System | Shape memory polymer container closure device |
Non-Patent Citations (14)
Title |
---|
Chinese Patent Office, First Office Action and Search Report dated Apr. 16, 2020 in Chinese patent application No. 01680064779.0, 20 pages total. |
European Patent Office, Communication pursuant to Rules 70(2) and 70a(2) EPC dated Jan. 8, 2019, in European Patent Application No. 16783914.1, 12 pages. |
European Patent Office, Extended European Search Report dated Apr. 26, 2019 in European Patent Application No. 16843059.3. |
Japan Patent Office, Notice of Reason(s) for Rejection dated Jan. 8, 2019 in Japanese Patent Application No. 2018-511680, eight pages. |
Japanese Patent Office, Notice of Reason(s) for Rejection dated Jan. 14, 2020 in Japanese Patent Application No. 2019-078450, 10 pages total. |
Landsman et al., "Design and verification of a shape memory polymer peripheral occlusion device," Journal of the Mechanical Behavior of Biomedical Materials, Jun. 23, 2016, pp. 195-206, vol. 63, Elsevier Ltd. |
Rodriguez et al., "Reticulation of low density shape memory polymer foam with an in vivo demonstration of vascular occlusion," Journal of the Mechanical Behavior of Biomedical Materials, Aug. 11, 2014, pp. 102-114, vol. 40, Elsevier Ltd. |
Singhal et al., "Ultra Low Density and Highly Crosslinked Biocompatible Shape Memory Polyurethane Foams," Journal of Polymer Sciences B Polymer Physics, May 15, 2012, pp. 1-27, vol. 50, Issue 10, National Institutes of Health. |
Singhal, et al., "Low density biodegradable shape memory polyurethane foams for embolic biomedical applications," Acta Biomaterial, Jan. 2014, pp. 67-76, vol. 10, issue 1, Elsevier Ltd. |
The International Searching Authority, "Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority", dated Jul. 28, 2016 in International Application No. PCT/US2016/028789, 16 pages. |
The International Searching Authority, Written Opinion of the International Searching Authority and the International Search Report dated Nov. 21, 2016 in International Application No. PCT/US16/50097, seven pages. |
Wierzbicki, et al.; "Mechanical and in vitro evaluation of an experimental canine patent ductus arteriosus occlusion device", available on-line Dec. 21, 2015, pp. 156-167, Journal of the Mechanical Behavior of Biomedical Materials 59, Elsevier Ltd. |
Wikipedia, "Cone," Aug. 30, 2016, 6 pages, https://en.wikipedia.org/wiki/Cone. |
Wikipedia, "Pseudoelasticity," Aug. 30, 2016, 2 pages, https://en.wikipedia.org/wiki/Pseudoelasticity. |
Also Published As
Publication number | Publication date |
---|---|
US20220323079A1 (en) | 2022-10-13 |
US11369385B2 (en) | 2022-06-28 |
JP6517432B2 (en) | 2019-05-22 |
PL3344161T3 (en) | 2024-05-06 |
JP2020168396A (en) | 2020-10-15 |
CN108430345A (en) | 2018-08-21 |
EP4316386A2 (en) | 2024-02-07 |
JP2019111420A (en) | 2019-07-11 |
JP7130817B2 (en) | 2022-09-05 |
JP6720381B2 (en) | 2020-07-08 |
JP2018526128A (en) | 2018-09-13 |
US20190015108A1 (en) | 2019-01-17 |
JP6900556B2 (en) | 2021-07-07 |
US20210015485A1 (en) | 2021-01-21 |
JP7318081B2 (en) | 2023-07-31 |
CN108430345B (en) | 2021-03-12 |
CN112890904A (en) | 2021-06-04 |
EP3344161B1 (en) | 2023-12-20 |
EP3344161A4 (en) | 2019-05-22 |
JP2022171685A (en) | 2022-11-11 |
WO2017040918A1 (en) | 2017-03-09 |
EP4316386A3 (en) | 2024-04-24 |
JP2021164658A (en) | 2021-10-14 |
US11944317B2 (en) | 2024-04-02 |
EP3344161A1 (en) | 2018-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11944317B2 (en) | Shape memory polymer vessel occlusion device | |
US8784442B2 (en) | Methods and systems for performing thrombectomy procedures | |
JP4741728B2 (en) | Intravascular thin film device and stroke treatment | |
EP1549229B1 (en) | Device for closure of a vascular defect | |
US20060116709A1 (en) | Aneurysm treatment devices and methods | |
EP3622901A1 (en) | Aneurysm occlusion device | |
JP2007531560A (en) | Devices and methods for endovascular treatment | |
US11229440B2 (en) | Systems and methods for vascular occlusion | |
US20150238195A1 (en) | Methods and systems for performing intralumenal procedures | |
US20130046326A1 (en) | Methods and systems for performing intralumenal procedures | |
WO2010096541A1 (en) | Vascular occlusion devices and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:TEXAS ENGINEERING EXPERIMENT STATION;REEL/FRAME:045860/0347 Effective date: 20180330 Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:TEXAS ENGINEERING EXPERIMENT STATION;REEL/FRAME:045860/0347 Effective date: 20180330 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: SHAPE MEMORY MEDICAL, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GLOWCZWSKI, ALAN C.;REEL/FRAME:051510/0486 Effective date: 20200110 Owner name: SHAPE MEMORY MEDICAL, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GLOWCZWSKI, ALAN C.;REEL/FRAME:051510/0528 Effective date: 20200110 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: THE TEXAS A&M UNIVERSITY SYSTEM, TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAITLAND, DUNCAN J.;LANDSMAN, TODD L.;RODRIGUEZ, JENNIFER NICOLE;AND OTHERS;SIGNING DATES FROM 20200122 TO 20220216;REEL/FRAME:059035/0772 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |